Volume 26, Issue 3, Pages (March 2018)

Slides:



Advertisements
Similar presentations
Fig. 2. The expression of pKr-2 in the substantia nigra (SN) of patients with Parkinson's disease (PD). (A, B) Western blot analysis for pKr-1-2 and pKr-2,
Advertisements

Molecular Therapy - Methods & Clinical Development
Targeting Visceral Fat by Intraperitoneal Delivery of Novel AAV Serotype Vector Restricting Off-Target Transduction in Liver  Wei Huang, Xianglan Liu,
Volume 26, Issue 4, Pages (April 2018)
Volume 69, Issue 6, Pages (March 2006)
Xiang Li, Feng Xu, Ekapun Karoopongse, A
Volume 7, Issue 3, Pages (May 2014)
Volume 8, Issue 4, Pages (October 2008)
Volume 15, Issue 8, Pages (May 2016)
Volume 3, Issue 5, Pages (May 2006)
Volume 140, Issue 5, Pages (May 2011)
Volume 20, Issue 6, Pages (December 2014)
Liver X Receptor Activators Display Anti-Inflammatory Activity in Irritant and Allergic Contact Dermatitis Models: Liver-X-Receptor-Specific Inhibition.
Molecular Therapy - Methods & Clinical Development
Volume 16, Issue 4, Pages (April 2008)
Volume 6, Issue 3, Pages (September 2007)
Volume 128, Issue 5, Pages (May 2005)
Molecular Therapy - Nucleic Acids
Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene
Molecular Therapy - Methods & Clinical Development
Volume 25, Issue 6, Pages (June 2017)
Volume 25, Issue 11, Pages (November 2017)
Volume 26, Issue 2, Pages (February 2018)
Volume 22, Issue 4, Pages (January 2018)
Volume 26, Issue 4, Pages (April 2018)
Volume 18, Issue 13, Pages (March 2017)
Targeting Visceral Fat by Intraperitoneal Delivery of Novel AAV Serotype Vector Restricting Off-Target Transduction in Liver  Wei Huang, Xianglan Liu,
Volume 25, Issue 1, Pages (January 2017)
Scalable Production of AAV Vectors in Orbitally Shaken HEK293 Cells
Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type I  Cristina Martin-Higueras,
Volume 16, Issue 7, Pages (August 2016)
Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene
Molecular Therapy - Methods & Clinical Development
Volume 25, Issue 3, Pages (March 2017)
Heat Shock Transcription Factor 1 Is a Key Determinant of HCC Development by Regulating Hepatic Steatosis and Metabolic Syndrome  Xiongjie Jin, Demetrius.
Codon-Optimized P1A-Encoding DNA Vaccine: Toward a Therapeutic Vaccination against P815 Mastocytoma  Alessandra Lopes, Kevin Vanvarenberg, Véronique Préat,
Volume 9, Issue 5, Pages (May 2009)
Molecular Therapy - Nucleic Acids
Liver X Receptor Activators Display Anti-Inflammatory Activity in Irritant and Allergic Contact Dermatitis Models: Liver-X-Receptor-Specific Inhibition.
Volume 9, Issue 6, Pages (December 2014)
Molecular Therapy - Methods & Clinical Development
Volume 25, Issue 10, Pages (October 2017)
Volume 14, Issue 4, Pages (October 2011)
Computer-assisted Hydrodynamic Gene Delivery
Volume 5, Issue 6, Pages (June 2002)
Xin Xie, Tomas Venit, Nizar Drou, Piergiorgio Percipalle
The RNA-Binding Protein NONO Coordinates Hepatic Adaptation to Feeding
Volume 15, Issue 2, Pages (April 2016)
Volume 25, Issue 4, Pages (April 2017)
Volume 25, Issue 11, Pages (November 2017)
Volume 27, Issue 4, Pages e4 (April 2018)
Volume 26, Issue 1, Pages (January 2018)
Volume 6, Issue 4, Pages (October 2007)
Volume 26, Issue 3, Pages (March 2018)
Volume 18, Issue 6, Pages (June 2010)
Volume 21, Issue 3, Pages (March 2013)
Molecular Therapy - Oncolytics
Arisa Hirano, Daniel Braas, Ying-Hui Fu, Louis J. Ptáček  Cell Reports 
Molecular Therapy - Nucleic Acids
Volume 1, Issue 4, Pages (April 2000)
Volume 13, Issue 2, Pages (February 2006)
Volume 26, Issue 2, Pages e3 (January 2019)
Molecular Therapy - Methods & Clinical Development
Irreplaceability of Neuronal Ensembles after Memory Allocation
Arati Sridharan, Chetan Patel, Jit Muthuswamy 
Role of Cell-Penetrating Peptides in Intracellular Delivery of Peptide Nucleic Acids Targeting Hepadnaviral Replication  Bénédicte Ndeboko, Narayan Ramamurthy,
Chen Wu, Michelle E. Watts, Lee L. Rubin  Cell Reports 
Volume 27, Issue 9, Pages (September 2019)
Molecular Therapy - Methods & Clinical Development
Aminoglycoside Enhances the Delivery of Antisense Morpholino Oligonucleotides In Vitro and in mdx Mice  Mingxing Wang, Bo Wu, Sapana N. Shah, Peijuan.
Presentation transcript:

Volume 26, Issue 3, Pages 814-821 (March 2018) G6PC mRNA Therapy Positively Regulates Fasting Blood Glucose and Decreases Liver Abnormalities in a Mouse Model of Glycogen Storage Disease 1a  Daniel S. Roseman, Tayeba Khan, Fabienne Rajas, Lucy S. Jun, Kirtika H. Asrani, Cleo Isaacs, Jeremiah D. Farelli, Romesh R. Subramanian  Molecular Therapy  Volume 26, Issue 3, Pages 814-821 (March 2018) DOI: 10.1016/j.ymthe.2018.01.006 Copyright © 2018 The Author(s) Terms and Conditions

Molecular Therapy 2018 26, 814-821DOI: (10.1016/j.ymthe.2018.01.006) Copyright © 2018 The Author(s) Terms and Conditions

Figure 1 Effect of mRNA Therapy after 72 hr on Fasting Glycemia (A) Fasting blood glucose levels were monitored for 9 hr in GFP mRNA-treated WT mice (red circles), GFP mRNA-treated L.G6PC−/− mice (green circles), G6PC-WT-treated L.G6PC−/− mice (purple circles), G6PC-V1-treated L.G6PC−/− mice (orange circles), and G6PC-V2-treated L.G6PC−/− mice (black circles). (B) Areas under the curve (AUCs) were calculated from each fasting glucose curve, and individual treatment groups (n = 5 or 6) are shown, with bars representing the mean ± 95% confidence interval (CI). The groups were compared by one-way ANOVA followed by Dunnett’s comparison test. Values significantly different from GFP-treated L.G6PC−/− mice (***p < 0.0005) are indicated. Molecular Therapy 2018 26, 814-821DOI: (10.1016/j.ymthe.2018.01.006) Copyright © 2018 The Author(s) Terms and Conditions

Figure 2 Effect of mRNA Therapy after 96 hr on Hepatic Biomarkers (A) Liver weight as percentage of total body weight, (B) hepatic G6P content, (C) hepatic glycogen content, and (D) hepatic triglyceride content in GFP mRNA-treated WT mice (red circles), GFP mRNA-treated L.G6PC−/− mice (green circles), G6PC-WT-treated L.G6PC−/− mice (purple circles), G6PC-V1-treated L.G6PC−/− mice (orange circles), and G6PC-V2-treated L.G6PC−/− mice (black circles). Data were obtained from mice fasted for 24 hr, and individual treatment groups (n = 5 or 6) are shown, with bars representing the mean ± 95% CI. The groups were compared by one-way ANOVA followed by Dunnett’s comparison test. Values significantly different from GFP-treated L.G6PC−/− mice (*p < 0.05, **p < 0.005, and ***p < 0.0005) are indicated. Molecular Therapy 2018 26, 814-821DOI: (10.1016/j.ymthe.2018.01.006) Copyright © 2018 The Author(s) Terms and Conditions

Figure 3 Histological Analysis of the Liver after mRNA Therapy (A) Immunohistochemistry (IHC) of G6PC (brown staining) in the liver of (a) WT mice and (b) untreated L.G6PC−/− mice. Note vacuolated hepatocytes in the L.G6PC−/− sample. Immunohistochemistry of G6PC in the liver of L.G6PC−/− mice treated with (c) G6PC-WT, (d) G6PC-V1, and (e) G6PC-V2 mRNA at 96 hr post-treatment. Note the reduction of hepatocyte vacuolization and return to more WT-like hepatocyte morphology in the cells closest to the vein. (B) Distribution of human G6PC mRNA (brown dots) at 24 hr post-treatment in (a) WT mice, (b) GFP mRNA-treated L.G6PC−/− mice, (c) G6PC-WT-treated L.G6PC−/− mice, (d) G6PC-V1-treated L.G6PC−/− mice, and (e) G6PC-V2-treated L.G6PC−/− mice. Molecular Therapy 2018 26, 814-821DOI: (10.1016/j.ymthe.2018.01.006) Copyright © 2018 The Author(s) Terms and Conditions

Figure 4 Western Blot Analysis of G6Pase Expression over Time in Human Primary Hepatocytes Transfected with WT or Protein-Engineered mRNAs Cells transfected with human G6PC-WT (WT), G6PC-V1 (V1), and G6PC-V2 (V2) mRNAs were lysed at the indicated days post-transfection and analyzed via western blot using a rabbit anti-human G6Pase polyclonal Ab. Molecular Therapy 2018 26, 814-821DOI: (10.1016/j.ymthe.2018.01.006) Copyright © 2018 The Author(s) Terms and Conditions

Figure 5 Effect of mRNA Therapy on Fasting Glycemia 6 and 11 Days Post-Treatment Plot of fasting blood glucose levels to 9 hr following (A) 6 days and (B) 11 days of mRNA dosing. GFP mRNA-treated WT mice (red circles), GFP mRNA-treated L.G6PC−/− mice (green circles), G6PC-WT-treated L.G6PC−/− mice (purple circles), G6PC-V1-treated L.G6PC−/− mice (orange circles), and G6PC-V2-treated L.G6PC−/− mice (black circles). AUCs were calculated from the plots of (C) 6 days and (D) 11 days, and individual treatment groups (n = 5 or 6) are shown, with bars representing the mean ± 95% CI. The groups were compared by one-way ANOVA followed by Dunnett’s comparison test. Values significantly different from GFP-treated L.G6PC−/− mice (**p < 0.005 and ***p < 0.0001) are indicated. Molecular Therapy 2018 26, 814-821DOI: (10.1016/j.ymthe.2018.01.006) Copyright © 2018 The Author(s) Terms and Conditions

Figure 6 Effect of mRNA Therapy on Liver Weight at 7 and 12 Days Liver weight as a percentage of total body weight after (A) 7 days or (B) 12 days post-dose. GFP mRNA-treated WT mice (red circles), GFP mRNA-treated L.G6PC−/− mice (green circles), G6PC-WT-treated L.G6PC−/− mice (purple circles), G6PC-V1-treated L.G6PC−/− mice (orange circles), and G6PC-V2-treated L.G6PC−/− mice (black circles). Data were obtained from mice fasted for 24 hr, and individual treatment groups (n = 5 or 6) are shown, with bars representing the mean ± 95% CI. The groups were compared by one-way ANOVA followed by Dunnett’s comparison test. Values significantly different from GFP-treated L.G6PC−/− mice (*p < 0.05, **p < 0.005, and ***p < 0.0005) are indicated. Molecular Therapy 2018 26, 814-821DOI: (10.1016/j.ymthe.2018.01.006) Copyright © 2018 The Author(s) Terms and Conditions